Pyxis Oncology Inc
PYXS3.910USD
-0.130-3.22%
收盘 11/07, 16:00（美东）报价延迟15分钟
243.01M总市值
亏损市盈率 TTM
关于 Pyxis Oncology Inc 公司
Pyxis Oncology, Inc. 是一家临床阶段公司，专注于开发针对难治性癌症的疗法。该公司正在开发具有单一疗法和联合疗法潜力的疗法。其临床项目组合包括 PYX-201、PYX-106 和 PYX-107。PYX-201 是一种抗体-药物偶联物 (ADC)，可靶向肿瘤基质内的 Extradomain-B 纤连蛋白，而 PYX-106 是一种完全人类 Siglec-15 靶向抗体，旨在阻止对 T 细胞增殖和功能的抑制，目前正在针对多种类型的实体瘤进行 1 期临床研究评估。PYX-107 是一种 CD40 激动剂抗体，旨在最大限度地发挥其激动特性。其治疗候选药物旨在直接杀死肿瘤细胞并解决癌症造成的潜在病理，导致其无法控制的增殖和免疫逃避。其 ADC 和免疫肿瘤学 (IO) 项目针对一系列对现行治疗标准有抗药性的实体肿瘤。
Pyxis Oncology Inc简介
公司代码PYXS
公司名称Pyxis Oncology Inc
上市日期Oct 08, 2021
CEODr. Lara S. Sullivan, M.D.
员工数量44
证券类型Ordinary Share
年结日Oct 08
公司地址321 Harrison Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02118
电话16172219059
网址https://pyxisoncology.com/
公司代码PYXS
上市日期Oct 08, 2021
CEODr. Lara S. Sullivan, M.D.
Pyxis Oncology Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
393.42K
+50.20%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
+16.29%
Dr. Freda C. Lewis-Hall, M.D.
Dr. Freda C. Lewis-Hall, M.D.
Independent Director
Independent Director
241.41K
+17.08%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
-75.40%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Rachel W. Humphrey, M.D.
Dr. Rachel W. Humphrey, M.D.
Independent Director
Independent Director
--
--
Mr. John L. Flavin
Mr. John L. Flavin
Independent Chairman Of The Board
Independent Chairman Of The Board
--
--
Dr. Lara S. Sullivan, M.D.
Dr. Lara S. Sullivan, M.D.
Director, President, Chief Executive Officer and Chief Medical Officer
Director, President, Chief Executive Officer and Chief Medical Officer
--
--
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
393.42K
+50.20%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
+16.29%
Dr. Freda C. Lewis-Hall, M.D.
Dr. Freda C. Lewis-Hall, M.D.
Independent Director
Independent Director
241.41K
+17.08%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
-75.40%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 21 分钟前
更新时间: 21 分钟前
持股股东
股东类型
持股股东
持股股东
占比
Pfizer Inc
11.29%
GordonMD Global Investments LP
6.16%
Laurion Capital Management LP
5.82%
Bayer World Investments BV
4.40%
Tang Capital Management, LLC
4.02%
其他
68.30%
持股股东
持股股东
占比
Pfizer Inc
11.29%
GordonMD Global Investments LP
6.16%
Laurion Capital Management LP
5.82%
Bayer World Investments BV
4.40%
Tang Capital Management, LLC
4.02%
其他
68.30%
股东类型
持股股东
占比
Corporation
15.76%
Hedge Fund
15.38%
Investment Advisor
13.33%
Individual Investor
7.62%
Investment Advisor/Hedge Fund
3.84%
Research Firm
1.38%
Venture Capital
0.83%
Bank and Trust
0.10%
Endowment Fund
0.08%
其他
41.69%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
203
21.67M
34.95%
-17.94M
2025Q2
209
38.70M
62.47%
-13.38M
2025Q1
216
38.34M
62.12%
-14.52M
2024Q4
213
39.78M
66.90%
-17.18M
2024Q3
192
46.99M
81.54%
-6.22M
2024Q2
176
47.00M
84.53%
-2.80M
2024Q1
171
42.24M
77.42%
+2.97M
2023Q4
155
21.66M
52.75%
-11.58M
2023Q3
153
21.37M
52.33%
-11.59M
2023Q2
144
21.88M
56.33%
-9.87M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Pfizer Inc
7.03M
11.34%
--
--
Jun 30, 2025
GordonMD Global Investments LP
3.83M
6.18%
+3.83M
--
Jul 14, 2025
Laurion Capital Management LP
3.63M
5.85%
--
--
Jun 30, 2025
Bayer World Investments BV
2.74M
4.42%
--
--
Sep 30, 2024
Tang Capital Management, LLC
2.50M
4.03%
+1.40M
+127.27%
Jun 30, 2025
The Vanguard Group, Inc.
2.15M
3.47%
-287.33K
-11.79%
Jun 30, 2025
Sullivan (Lara S. M.D.)
1.87M
3.01%
-537.34K
-22.35%
Apr 21, 2025
Connealy (Pamela Ann)
1.20M
1.93%
+670.09K
+126.66%
Apr 21, 2025
Palo Alto Investors LP
1.04M
1.67%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
864.53K
1.39%
-2.10M
-70.84%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Tema Oncology ETF
0%
Avantis US Small Cap Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
Tema Oncology ETF
占比0%
Avantis US Small Cap Value ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
